Selected research
Industry Research
Neuroblastoma Treatment Industry Research Report 2026
Market perspective
The global Neuroblastoma Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Neuroblastoma Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Neuroblastoma Treatment market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Neuroblastoma Treatment market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Neuroblastoma Treatment include Adaptimmune, CureSearch, Juno Therapeutics, Kite Pharma, NANT, Seattle Children’s, Texas Children’s, Fosun Pharmaceutical and Jiangsu Hengrui Medicine Co.,Ltd., among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Neuroblastoma Treatment market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Neuroblastoma Treatment.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Neuroblastoma Treatment Market by Company
Adaptimmune
CureSearch
Juno Therapeutics
Kite Pharma
NANT
Seattle Children’s
Texas Children’s
Fosun Pharmaceutical
Jiangsu Hengrui Medicine Co.,Ltd.
Novartis
Sino Biopharmaceutical
Neuroblastoma Treatment Segment by Type
Vaccine Therapy
Oncolytic Virus Therapy
Chimeric Antigen Receptor T-Cell Immunotherapy
Combination Chemotherapy
Monoclonal Antibody Therapy
Neuroblastoma Treatment Segment by Application
Hospitals
Clinics
Others
Neuroblastoma Treatment Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroblastoma Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neuroblastoma Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroblastoma Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Neuroblastoma Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Vaccine Therapy
- Oncolytic Virus Therapy
- Chimeric Antigen Receptor T-Cell Immunotherapy
- Combination Chemotherapy
- Monoclonal Antibody Therapy
Applications
- Hospitals
- Clinics
- Others
Companies covered
- Adaptimmune
- CureSearch
- Juno Therapeutics
- Kite Pharma
- NANT
- Seattle Children’s
- Texas Children’s
- Fosun Pharmaceutical
- Jiangsu Hengrui Medicine Co.,Ltd.
- Novartis
- Sino Biopharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Neuroblastoma Treatment by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Vaccine Therapy
- 2.2.3 Oncolytic Virus Therapy
- 2.2.4 Chimeric Antigen Receptor T-Cell Immunotherapy
- 2.2.5 Combination Chemotherapy
- 2.2.6 Monoclonal Antibody Therapy
- 2.3 Neuroblastoma Treatment by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospitals
- 2.3.3 Clinics
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Neuroblastoma Treatment Breakdown Data by Type
- 3.1 Global Neuroblastoma Treatment Historic Market Size by Type (2021-2026)
- 3.2 Global Neuroblastoma Treatment Forecasted Market Size by Type (2027-2032)
4 Neuroblastoma Treatment Breakdown Data by Application
- 4.1 Global Neuroblastoma Treatment Historic Market Size by Application (2021-2026)
- 4.2 Global Neuroblastoma Treatment Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Neuroblastoma Treatment Market Perspective (2021-2032)
- 5.2 Global Neuroblastoma Treatment Growth Trends by Region
- 5.2.1 Global Neuroblastoma Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Neuroblastoma Treatment Historic Market Size by Region (2021-2026)
- 5.2.3 Neuroblastoma Treatment Forecasted Market Size by Region (2027-2032)
- 5.3 Neuroblastoma Treatment Market Dynamics
- 5.3.1 Neuroblastoma Treatment Industry Trends
- 5.3.2 Neuroblastoma Treatment Market Drivers
- 5.3.3 Neuroblastoma Treatment Market Challenges
- 5.3.4 Neuroblastoma Treatment Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Neuroblastoma Treatment Players by Revenue
- 6.1.1 Global Top Neuroblastoma Treatment Players by Revenue (2021-2026)
- 6.1.2 Global Neuroblastoma Treatment Revenue Market Share by Players (2021-2026)
- 6.2 Global Neuroblastoma Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Neuroblastoma Treatment Head Office and Area Served
- 6.4 Global Neuroblastoma Treatment Players, Product Type & Application
- 6.5 Global Neuroblastoma Treatment Manufacturers Established Date
- 6.6 Global Neuroblastoma Treatment Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Neuroblastoma Treatment Market Size (2021-2032)
- 7.2 North America Neuroblastoma Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Neuroblastoma Treatment Market Size by Country (2021-2026)
- 7.4 North America Neuroblastoma Treatment Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Neuroblastoma Treatment Market Size (2021-2032)
- 8.2 Europe Neuroblastoma Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Neuroblastoma Treatment Market Size by Country (2021-2026)
- 8.4 Europe Neuroblastoma Treatment Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Neuroblastoma Treatment Market Size (2021-2032)
- 9.2 Asia-Pacific Neuroblastoma Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Neuroblastoma Treatment Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Neuroblastoma Treatment Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Neuroblastoma Treatment Market Size (2021-2032)
- 10.2 South America Neuroblastoma Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Neuroblastoma Treatment Market Size by Country (2021-2026)
- 10.4 South America Neuroblastoma Treatment Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Neuroblastoma Treatment Market Size (2021-2032)
- 11.2 Middle East & Africa Neuroblastoma Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Neuroblastoma Treatment Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Neuroblastoma Treatment Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Adaptimmune
- 12.1.1 Adaptimmune Company Information
- 12.1.2 Adaptimmune Business Overview
- 12.1.3 Adaptimmune Revenue in Neuroblastoma Treatment Business (2021-2026)
- 12.1.4 Adaptimmune Neuroblastoma Treatment Product Portfolio
- 12.1.5 Adaptimmune Recent Developments
- 12.2 CureSearch
- 12.2.1 CureSearch Company Information
- 12.2.2 CureSearch Business Overview
- 12.2.3 CureSearch Revenue in Neuroblastoma Treatment Business (2021-2026)
- 12.2.4 CureSearch Neuroblastoma Treatment Product Portfolio
- 12.2.5 CureSearch Recent Developments
- 12.3 Juno Therapeutics
- 12.3.1 Juno Therapeutics Company Information
- 12.3.2 Juno Therapeutics Business Overview
- 12.3.3 Juno Therapeutics Revenue in Neuroblastoma Treatment Business (2021-2026)
- 12.3.4 Juno Therapeutics Neuroblastoma Treatment Product Portfolio
- 12.3.5 Juno Therapeutics Recent Developments
- 12.4 Kite Pharma
- 12.4.1 Kite Pharma Company Information
- 12.4.2 Kite Pharma Business Overview
- 12.4.3 Kite Pharma Revenue in Neuroblastoma Treatment Business (2021-2026)
- 12.4.4 Kite Pharma Neuroblastoma Treatment Product Portfolio
- 12.4.5 Kite Pharma Recent Developments
- 12.5 NANT
- 12.5.1 NANT Company Information
- 12.5.2 NANT Business Overview
- 12.5.3 NANT Revenue in Neuroblastoma Treatment Business (2021-2026)
- 12.5.4 NANT Neuroblastoma Treatment Product Portfolio
- 12.5.5 NANT Recent Developments
- 12.6 Seattle Children’s
- 12.6.1 Seattle Children’s Company Information
- 12.6.2 Seattle Children’s Business Overview
- 12.6.3 Seattle Children’s Revenue in Neuroblastoma Treatment Business (2021-2026)
- 12.6.4 Seattle Children’s Neuroblastoma Treatment Product Portfolio
- 12.6.5 Seattle Children’s Recent Developments
- 12.7 Texas Children’s
- 12.7.1 Texas Children’s Company Information
- 12.7.2 Texas Children’s Business Overview
- 12.7.3 Texas Children’s Revenue in Neuroblastoma Treatment Business (2021-2026)
- 12.7.4 Texas Children’s Neuroblastoma Treatment Product Portfolio
- 12.7.5 Texas Children’s Recent Developments
- 12.8 Fosun Pharmaceutical
- 12.8.1 Fosun Pharmaceutical Company Information
- 12.8.2 Fosun Pharmaceutical Business Overview
- 12.8.3 Fosun Pharmaceutical Revenue in Neuroblastoma Treatment Business (2021-2026)
- 12.8.4 Fosun Pharmaceutical Neuroblastoma Treatment Product Portfolio
- 12.8.5 Fosun Pharmaceutical Recent Developments
- 12.9 Jiangsu Hengrui Medicine Co.,Ltd.
- 12.9.1 Jiangsu Hengrui Medicine Co.,Ltd. Company Information
- 12.9.2 Jiangsu Hengrui Medicine Co.,Ltd. Business Overview
- 12.9.3 Jiangsu Hengrui Medicine Co.,Ltd. Revenue in Neuroblastoma Treatment Business (2021-2026)
- 12.9.4 Jiangsu Hengrui Medicine Co.,Ltd. Neuroblastoma Treatment Product Portfolio
- 12.9.5 Jiangsu Hengrui Medicine Co.,Ltd. Recent Developments
- 12.10 Novartis
- 12.10.1 Novartis Company Information
- 12.10.2 Novartis Business Overview
- 12.10.3 Novartis Revenue in Neuroblastoma Treatment Business (2021-2026)
- 12.10.4 Novartis Neuroblastoma Treatment Product Portfolio
- 12.10.5 Novartis Recent Developments
- 12.11 Sino Biopharmaceutical
- 12.11.1 Sino Biopharmaceutical Company Information
- 12.11.2 Sino Biopharmaceutical Business Overview
- 12.11.3 Sino Biopharmaceutical Revenue in Neuroblastoma Treatment Business (2021-2026)
- 12.11.4 Sino Biopharmaceutical Neuroblastoma Treatment Product Portfolio
- 12.11.5 Sino Biopharmaceutical Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst